This trial is unknown!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Percutaneous Coronary Intervention
and you are
between 18 and 80
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

Patients undergoing the percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) are enrolled. All patients will be randomized to receive either 12 months or 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist in addition to aspirin, all patients continue receiving aspirin indefinitely. The primary efficacy end points of this study are the incidence of a composite end point including all cause deaths, myocardial infarction, the incidence of Academic Research Consortium defined definite or probable stent thrombosis and stroke (MACCE) at 24 months. The primary safety end point is the incidence of GUSTO moderate or severe bleeding.

Provided treatments

  • Drug: 12 months of P2Y12 receptor antagonist
  • Drug: 24 months of P2Y12 receptor antagonist
  • Drug: Aspirin
Tris trial is registered with FDA with number: NCT02402491. The sponsor of the trial is Beijing Anzhen Hospital and it is looking for 1000 volunteers for the current phase.
Official trial title:
Twelve Versus 24 Months of Dual Antiplatelet Therapy in Patients With Percutaneous Coronary Intervention for In-stent Restenosis